

AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA373)

NICE GUIDANCE ISSUED DECEMBER 2015

(Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology)

Final Appraisal Recommendation

Advice No: 3513 – November 2013

Etanercept (Enbrel[®]) 10 mg and 25 mg powder and solvent for solution for injection and pre-filled syringe and 50 mg pre-filled syringe and pre-filled pen

Limited submission by Pfizer Ltd

Recommendation of AWMSG

Etanercept (Enbrel[®]) is recommended as an option for use within NHS Wales for the treatment of:

- **polyarthritis (rheumatoid factor positive or negative) in children aged 2 to < 4 years and extended oligoarthritis in children and adolescents ≥ 2 years who have had an inadequate response to, or who have proved intolerant of, methotrexate;**
- **psoriatic arthritis in adolescents ≥ 12 years who have had an inadequate response to, or who have proved intolerant of, methotrexate;**
- **enthesitis-related arthritis in adolescents ≥ 12 years who have had an inadequate response to, or who have proved intolerant of, conventional therapy.**

Additional notes:

- Please refer to the Summaries of Product Characteristics for the full licensed indication.
- National Institute for Health and Care Excellence Technology Appraisal 35 (TA35) provides guidance on etanercept for the treatment of children with polyarthritis aged ≥ 4 years.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 1437), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the



NICE has accredited the process used by the All Wales Medicines Strategy Group (AWMSG) to produce its final appraisal recommendation. Accreditation is valid for 5 years from October 2011. More information on accreditation can be viewed at www.evidence.nhs.uk.

For full details on our accreditation visit: www.nice.org.uk/accreditation.

PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation was ratified by the Minister for Health and Social Services in December 2013 and will be considered for review in December 2016.

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group. Final Appraisal Recommendation – 3513. Etanercept (Enbrel®) 10 mg and 25 mg powder and solvent for solution for injection and pre-filled syringe and 50 mg pre-filled syringe and pre-filled pen. November 2013.